Dr. Barinder Paul Bassi, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 100 S Bliss Ave, Tahlequah, OK 74464 Phone: 918-207-3780 Fax: 918-207-3781 |
Reed Karl Burk, D.P.M. Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 1105 E Allen Rd, Tahlequah, OK 74464 Phone: 918-931-1471 Fax: 918-458-9977 |
Ann Nguyen, D.P.M Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 19600 E Ross St, Tahlequah, OK 74464 Phone: 539-234-1000 |
Northeastern Foot Care Pllc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 217 N Muskogee, Tahlequah, OK 74464 Phone: 918-456-3222 Fax: 918-456-3196 |
Dr. Wendy Carmel Mcclain, D.P.M. Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 19600 E Ross St, Tahlequah, OK 74464 Phone: 539-234-1000 |
Lsi Foot Clinic Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 215 Woodlawn Ave, Tahlequah, OK 74464 Phone: 918-458-9888 Fax: 918-458-9977 |
News Archive
It's the gift that keeps on giving, from early fall, through the holiday season and into late spring. It's seasonal flu, caused by a virus that can fly through the air, hitch a ride on a handshake, hug or kiss, and is extremely good at infecting people and making them sick.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, particularly in China. However, HCC remains one of the more difficult cancers to treat. It is important to screen for new anti-cancer drugs. A number of dietary compounds possess anti-cancer properties. These dietary compounds may modify the activity of specific targets that control cell proliferation and apoptosis. Galangin could inhibit the methoxyresorufin O-demethylase activity of CYP1A2, CYP1A1 and P-form phenolsulfotransferase.
Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics with personal nutrition and lifestyle programs for patients with or at risk for heart disease, has received $1.0 million in additional tax incentives through the Life Sciences Tax Incentive Program.
Phase III clinical study comparing placebo to rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers, showed that overweight or obese people taking rimonabant 20mg once daily benefited from a significant reduction in their body weight
Health industry marketing research leader MD Analytics® released early results today from its annual Insight Syndication Report: Pharmacists Prescribing.
› Verified 6 days ago